Incyte Drug Cuts Bleeding Rate 81% in Early VWD Study
WILMINGTON, DE — Incyte (Nasdaq: INCY) reported that its experimental drug latarcibart reduced the median annualized bleeding rate by 81% in a 16-patient Phase 1/2 study, supporting the company’s decision …
Incyte Drug Cuts Bleeding Rate 81% in Early VWD Study Read More